<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03936140</url>
  </required_header>
  <id_info>
    <org_study_id>KC14MISI0880</org_study_id>
    <nct_id>NCT03936140</nct_id>
  </id_info>
  <brief_title>The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery</brief_title>
  <official_title>The Effect of Iloprost on Arterial Oxygenation and Shunt Fraction During One-lung Ventilation for Lung Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      During one-lung ventilation in patients undergoing thoracic surgery, the persistent flow in
      the non-ventilated lung increases intrapulmonary shunt and decreases systemic arterial
      oxygenation. This prospective, randomized, double blind study was conducted to evaluate the
      effects of inhaled iloprost during one-lung ventilation on arterial oxygenation and shunt
      fraction during thoracic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2018</start_date>
  <completion_date type="Actual">October 24, 2018</completion_date>
  <primary_completion_date type="Actual">October 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaO2(partial pressure of arterial oxygen)</measure>
    <time_frame>30 min after treatment</time_frame>
    <description>ABGA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary shunt fraction</measure>
    <time_frame>30 min after treatment</time_frame>
    <description>Qs/Qt = (CcO2-CaO2) / (CcO2-CvO2)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Iloprost 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iloprost 10μg of inhaled iloprost (Ventavis®)
Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iloprost 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iloprost 20μg of inhaled iloprost (Ventavis®)
Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Distilled water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Distilled water
Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled iloprost</intervention_name>
    <description>Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.</description>
    <arm_group_label>Iloprost 10</arm_group_label>
    <arm_group_label>Iloprost 20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Distilled water</intervention_name>
    <description>Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.</description>
    <arm_group_label>Distilled water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective video-assisted thoracoscopic surgery (VATS) lobectomy

          -  20 &lt; age &lt; 75

          -  American Society of Anesthesiologists (ASA) classification I~III

        Exclusion Criteria:

          -  ASA classification IV

          -  New York Heart Association (NYHA) class III~IV

          -  Severe obstructive lung disease / restrictive lung disease

          -  Pulmonary hypertension

          -  End-stage organ disease (i.e. hepatic failure, renal failure)

          -  Arrhythmia

          -  Previous history of thoracic surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wonjung Hwang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>May 1, 2019</last_update_submitted>
  <last_update_submitted_qc>May 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Wonjung Hwang</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

